Publications
Detailed Information
Molecular characterization and prognostic significance of FLT3 in CML progression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyung Im | - |
dc.contributor.author | Park, Juwon | - |
dc.contributor.author | Ahn, Kwang-Sung | - |
dc.contributor.author | Won, Nam-Hee | - |
dc.contributor.author | Shin, Wan Gyoon | - |
dc.contributor.author | Oh, Jung Mi | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Kim, Byoung Kook | - |
dc.date.accessioned | 2012-05-25T05:51:48Z | - |
dc.date.available | 2012-05-25T05:51:48Z | - |
dc.date.issued | 2010-08 | - |
dc.identifier.citation | LEUKEMIA RESEARCH; Vol.34 8; 995-1001 | ko_KR |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76468 | - |
dc.description.abstract | To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfection analysis was conducted to evaluate the role of FLT3, which was significantly upregulated in the blast crisis patients. Abl and c-Kit induction was detected in K562 cells transfected with FLT3 cDNA (K562/FLT3), and Abl and c-Kit levels were reduced in K562/FLT3 cells transfected with FLT3-siRNA (K562/FLT3-siRNA). The induction of FLT3 in CML cells attenuated imatinib-induced apoptosis. The opposite effect was observed in K562/FLT3-siRNA cells. An increased level of cleaved PARP and decreased level of pro-caspase 3 were noted when K562/FLT3-siRNA cells were treated with imatinib. These findings indicate that FLT3 is associated with disease progression, despite imatinib therapy. These results may help in the prediction of disease progression in CML patients and the development of more appropriate therapeutic modalities. (C) 2009 Elsevier Ltd. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | ko_KR |
dc.subject | Chronic myelogenous leukemia (CML) | ko_KR |
dc.subject | Fms-related tyrosine kinase 3 (FLT3) | ko_KR |
dc.subject | Imatinib | ko_KR |
dc.subject | Disease progression | ko_KR |
dc.subject | Resistance | ko_KR |
dc.title | Molecular characterization and prognostic significance of FLT3 in CML progression | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김경임 | - |
dc.contributor.AlternativeAuthor | 박주원 | - |
dc.contributor.AlternativeAuthor | 안광성 | - |
dc.contributor.AlternativeAuthor | 원남희 | - |
dc.contributor.AlternativeAuthor | 김병국 | - |
dc.contributor.AlternativeAuthor | 신완균 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.contributor.AlternativeAuthor | 오정미 | - |
dc.identifier.doi | 10.1016/j.leukres.2009.11.008 | - |
dc.citation.journaltitle | LEUKEMIA RESEARCH | - |
dc.description.citedreference | Hoshino K, 2009, LEUKEMIA RES, V33, P1361, DOI 10.1016/j.leukres.2009.03.044 | - |
dc.description.citedreference | Volpe G, 2009, CANCER LETT, V274, P1, DOI 10.1016/j.canlet.2008.06.003 | - |
dc.description.citedreference | Peng HL, 2008, CROAT MED J, V49, P650, DOI 10.3325/cmj.2008.5.650 | - |
dc.description.citedreference | Matsumura I, 2008, CANCER SCI, V99, P479, DOI 10.1111/j.1349-7006.2007.00717.x | - |
dc.description.citedreference | Kim BS, 2007, ANTI-CANCER DRUG, V18, P641 | - |
dc.description.citedreference | Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103 | - |
dc.description.citedreference | Yong ASM, 2006, BLOOD, V107, P205, DOI 10.1182/blood-2005-05-2155 | - |
dc.description.citedreference | Markovic A, 2005, INT J BIOCHEM CELL B, V37, P1168, DOI 10.1016/j.biocel.2004.12.005 | - |
dc.description.citedreference | ILARIA RL, 2005, HEMATOLOGY AM SOC HE, P188 | - |
dc.description.citedreference | Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579 | - |
dc.description.citedreference | Schmidt-Arras D, 2004, CURR PHARM DESIGN, V10, P1867 | - |
dc.description.citedreference | Kottaridis PD, 2003, BRIT J HAEMATOL, V122, P523 | - |
dc.description.citedreference | Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620 | - |
dc.description.citedreference | Marktel S, 2003, HAEMATOLOGICA, V88, P260 | - |
dc.description.citedreference | Ohmine K, 2003, STEM CELLS, V21, P315 | - |
dc.description.citedreference | Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274 | - |
dc.description.citedreference | Sawyers CL, 2002, BLOOD, V99, P3530 | - |
dc.description.citedreference | Ohmine K, 2001, ONCOGENE, V20, P8249 | - |
dc.description.citedreference | Sawyers CL, 1999, NEW ENGL J MED, V340, P1330 | - |
dc.description.citedreference | Savage DG, 1997, BRIT J HAEMATOL, V99, P30 | - |
dc.description.citedreference | Carow CE, 1996, BLOOD, V87, P1089 | - |
dc.description.citedreference | SILL H, 1995, BLOOD, V85, P2013 | - |
dc.description.citedreference | BIRG F, 1992, BLOOD, V80, P2584 | - |
dc.description.citedreference | AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783 | - |
dc.description.citedreference | KANTARJIAN HM, 1987, AM J MED, V83, P445 | - |
dc.description.citedreference | SOKAL JE, 1984, BLOOD, V63, P789 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.